Nov 7, 2026 · Science & Research Daily Digest
Science, space, biomedicine, and climate research highlights compiled for November 7, 2026, with summaries, links, and commentary.
I. Space & Deep Space
1. China’s space station: ODT rubidium BEC at 9.7 picokelvin equivalent temperature (ultracold atoms)
Summary:
Teams led by Xuzong Chen and Xiaoji Zhou at Peking University, with the Shanghai Institute of Optics and Fine Mechanics and partners, used Tiangong’s Cold Atom Physics Rack to prepare a Bose–Einstein condensate of about 2.0×10⁴ rubidium atoms in an optical dipole trap under microgravity. Tracking roughly 7.0 s of free expansion, they report an equivalent temperature of 9.7⁺³·²₋₂·₇ picokelvin—about one-quarter of the prior comparable record (~38 pK with ~2 s expansion). The work, “Quantum gases below 10 picokelvin in space,” appears in Science and is a landmark for all-optical cooling in orbit; longer coherent evolution times could aid equivalence-principle tests and atom interferometry.
Links:
- Science — Quantum gases below 10 picokelvin in space
- Peking University — Ultracold quantum gases below 10 pK on China’s space station
Commentary:
Gravity pins trap frequencies on the ground; Tiangong stretches the clock—ultracold races now hinge on seconds of free evolution, not only the picokelvin headline.
2. ESA’s Hera: first close-up of the Didymos system from ~60 km (planetary defense)
Summary:
ESA released Hera’s first close-up of the Didymos binary asteroids, taken with the monochromatic Asteroid Framing Camera from about 60 km. The ~780 m primary Didymos fills the frame; the ~151 m moonlet Dimorphos is mostly in shadow. Didymos still shows its equatorial ridge, but this face—opposite the side imaged by DART before the 2022 impact—looks markedly different, with boulders, craters, and groove- or ridge-like patterns. After a two-year cruise (~196.8 million km from Earth), Hera will turn kinetic deflection from a one-off demo into a better-constrained planetary-defense method; more detailed images of both bodies are planned for 25 November.
Links:
- ESA — Hera’s first close-up view of Didymos asteroids
- Space.com — Hera probe gets 1st good look at asteroid system
Commentary:
DART changed the orbit; Hera is the crash-site investigation—planetary defense needs post-impact mass, shape, and interior data before it becomes engineering, not anecdote.
II. Biomedicine & Health
3. Novartis pelacarsen: ~78% Lp(a) drop, but HORIZON CV outcomes stay neutral (cardiovascular)
Summary:
At AHA Scientific Sessions with simultaneous NEJM publication, the Phase 3 Lp(a) HORIZON trial in ~8,322 adults with established CVD and baseline Lp(a) ≥70 mg/dL across 42 countries found monthly subcutaneous pelacarsen cut Lp(a) by about 78.4% at one year. Over a median ~4.7 years, however, the primary composite of CV death, nonfatal MI, nonfatal stroke, or urgent revascularization occurred in ~12.3% on drug versus ~12.1% on placebo, with no benefit across subgroups or extended analyses. It is the first completed Phase 3 CV-outcomes study for an Lp(a)-targeted therapy; Novartis is largely shelving the atherosclerosis program while keeping a mid-stage valve-stenosis study.
Links:
- American Heart Association — Lp(a) HORIZON: Lp(a) fell 78%, outcomes neutral
- Cleveland Clinic — Pelacarsen did not reduce major CV events
Commentary:
A beautiful biomarker is not a hard endpoint—the Lp(a) field must still answer who, when, and how low before years of life are gained.
4. ZEUS: ziltivekimab slashes inflammation but not major CV events (anti-inflammatory)
Summary:
Also at AHA 2026, ZEUS enrolled ~6,376 adults with atherosclerotic CVD and chronic kidney disease randomized to monthly subcutaneous ziltivekimab 15 mg or placebo. At 24 months the drug cut hsCRP by ~64% and free IL-6 by ~76% versus placebo, with other inflammatory markers improving; yet over a median ~33 months, three-point MACE (CV death, nonfatal MI, or stroke) occurred in 17.6% versus 17.7% (HR 0.99, P=0.84). Paired with the same-day Lp(a) neutral result, it challenges the simple story that crushing inflammation or lipoprotein particles alone buys clinical events.
Links:
Commentary:
IL-6 blockade can put out the fire without rewriting plaque fate—anti-inflammatory CV drugs still have to clear the events bar, not the CRP curve.
5. J&J icotrokinra: Phase 3 win in biologic-naïve psoriatic arthritis (immunology)
Summary:
On 7 November Johnson & Johnson reported late-breaking ACR Convergence 2026 data: ICOTYDE (icotrokinra), a first-in-class once-daily oral peptide that blocks the IL-23 receptor, met the primary endpoint in ICONIC-PsA 1 among biologic-naïve adults with active PsA. At Week 16, ACR20 was 58% versus 41% on placebo, with ACR50 ~29% versus 16%; among those with qualifying skin disease, IGA 0/1 reached 57% versus 14% and PASI90 37% versus 6% (nominal P<0.001). Safety matched the known profile with no new signals. An oral IL-23R path could ease long-term joint-and-skin management now dominated by injectables.
Links:
Commentary:
Moving the IL-23 axis from needle to pill matters—adherence is part of efficacy when both joints and skin need years of control.
6. VGX-3100: China Phase 3 therapeutic HPV vaccine meets primary endpoint (oncology)
Summary:
Inovio/East-China partner plasmid DNA vaccine VGX-3100’s China Phase 3 HPV-303CHN (CTR20201547) was presented as an SITC LBA: led by Lingying Wu at Cancer Hospital CAMS across 22 sites, 207 women with HPV-16/18–positive cervical HSIL received intramuscular doses at weeks 0/4/12 with electroporation. At week 36, the composite primary endpoint (no histologic HSIL and clearance of HPV-16/18) was met in 52.5% (73/139) on vaccine versus 35.3% (24/68) on placebo—a 17.2-point difference (95% CI 2.7–30.6; P=0.025)—with no treatment-related serious adverse events. Platform sibling INO-3107 recently gained FDA accelerated approval; longer follow-up continues and the product is not yet approved in China.
Links:
Commentary:
Beyond cutting HSIL surgically, a quantified nonsurgical path is emerging—but longer follow-up must show dual histologic and viral clearance that lasts.
7. EPFL: secondary aptamers read conformation for small-molecule sandwich tests (molecular sensing)
Summary:
EPFL’s CHEMINA lab led by Nako Nakatsuka reports in Nature Chemistry a dual-aptamer architecture: a primary aptamer binds a small molecule and rearranges; a secondary aptamer recognizes that bound-state three-dimensional interface rather than the ligand itself, bypassing the dual-epitope barrier that blocks classic sandwich assays for tiny analytes. Secondary aptamers were isolated for three of four targets (serotonin, testosterone, DOG; not dopamine), and a naked-eye lateral-flow serotonin demo was built. The work expands DNA recognition from sequence complementarity to conformational epitopes.
Links:
- EPFL — A new sensing architecture to detect small molecules
- Nature Chemistry — Aptamers enable a distinct mode of conformational DNA recognition
Commentary:
Importing the “secondary antibody” logic into DNA—what small-molecule rapid tests lack is a second layer that reads shape change, not more gold particles.
III. Climate & Environment
8. Peking University: northwestern Tibetan ground ice thickens despite warming, driven by ~60% more precipitation (permafrost)
Summary:
Dongfeng Li’s group at Peking University, in Science Advances, reconstructed near-surface ground ice on the Tibetan Plateau for 1979–2018 using 369 boreholes plus physics–ML modeling. Roughly 35% of permafrost—mainly the westerly-controlled northwestern interior—gained ice at the active-layer base even as the region warmed; after 2000, annual precipitation in westerly zones rose ~60%, infiltrating and refreezing at persistently cold depths. Westerly regions gained ~+144 km³ of ice in the 0–3.2 m layer, offsetting monsoon-zone losses and yielding a plateau-wide near-surface net increase. Engineers and adaptation planners are urged to track rainfall-driven “permafrost anomalies,” not temperature alone.
Links:
- Peking University — Anomalous ground-ice increase on the Tibetan Plateau
- PKU News — Frozen ground gaining ice despite warming
Commentary:
“Warmer means melt” fails where precipitation rewrites the story—infrastructure risk maps painted only by temperature miss the thickening ice.
9. Tsinghua et al.: flash Joule heating upcycles wind blades into SiC/graphene (circular materials)
Summary:
Bing Deng, Hao Bi and colleagues at Tsinghua report in Chem Circularity that pulverized retired wind-turbine blades—silica-rich fiberglass in carbon-rich resin—heated by flash Joule heating to ~2000°C in about a second form silicon carbide plus graphene. In lab batches ~56% of the mix converted to a composite (~34% SiC / 66% graphene); just 0.3 wt% in epoxy raised tensile Young’s modulus ~27% and tensile strength ~11%, while 0.1 wt% lifted thermal diffusivity ~41%. Versus chemical dissolution, estimated GHG emissions drop by more than 90%, but the largest tested batch was ~10 g—scale-up and uniform heating remain open.
Links:
- C&EN — Using old wind turbine blades to make new ones
- Euronews — Flash heat could give turbine blades a second life
Commentary:
Blade end-of-life need not be landfill—one-second upcycling into a reinforcing additive is closer to closed-loop wind than downcycling shreds.
10. Italian study: ~0.5 m row spacing optimizes cooling in floating PV (renewables)
Summary:
Researchers at the University of Naples Parthenope and the University of Campania Luigi Vanvitelli used CFD on a proposed floating PV array at Italy’s Occhito Dam reservoir. In a three-row layout, spacing of about 0.5 module lengths cooled best: at 3.5 m/s wind, mean module temperature was ~27.16°C versus ~31.07°C for the densest pack, with the same layout also winning at 1.5 m/s. Wider gaps aid wake recovery but weaken inter-row airflow acceleration; the middle row is especially spacing-sensitive. The study warns floating PV designers not to assume “near water equals cool”—row spacing is a thermal design parameter.
Links:
Commentary:
Floating PV’s hidden yield is in heat rejection—packing one more row can give back the gains in higher cell temperature.
IV. Fundamental Research & Materials
11. Oxford: trapped ions simulate Aharonov–Bohm interference in a Z₂ lattice gauge theory (quantum simulation)
Summary:
Sebastian Saner and colleagues at the University of Oxford report in Nature Physics a hybrid trapped-ion simulation of a quasi-two-dimensional closed loop in a Z₂ lattice gauge theory that includes matter. Electronic states encode gauge fields and vibrations encode matter; zero flux allows tunneling while nonzero flux suppresses it—Aharonov–Bohm interference controlled by entangled gauge qubits. Most prior Z₂ simulations were one-dimensional and could not host flux or vison-like physics; the platform points toward higher-dimensional gauge theories and topological-error-correction-relevant experiments.
Links:
Commentary:
Stuffing flux into two entangled ions turns gauge links from paper variables into knobs experimenters can twist.
12. Jilin University et al.: single-dopant white OLED hits 27.1% EQE (optoelectronics)
Summary:
Jilin University and Ji Hua Laboratory report in National Science Review the MR-TADF emitter Th-DBN: a thiophene-bridged dual multi-resonance unit that emits ~499 nm blue-green as a monomer and ~588 nm orange-yellow as an excimer, both TADF channels, with doped-film PLQY ~98.8%. A warm-white single-dopant device (CIE ~0.35, 0.50) reached a maximum external quantum efficiency of 27.1% with ~2.4 V turn-on—said to nearly double the prior ceiling for purely organic single-dopant WOLEDs (often below ~15%)—and LT80 ~398 h at 1000 cd·m⁻².
Links:
- OLED-Info — Record-efficiency white OLED with single MR-TADF emitter
- National Science Review — Efficient white electroluminescence based on a single MR-TADF emitter
Commentary:
One molecule doing blue-green plus orange-yellow—simplifying white OLED stacks often beats stacking another RGB layer.
Today's Summary
- Tiangong pushed ultracold-atom equivalent temperature to 9.7 pK with ~7 s free expansion, while Hera delivered the first close look at Didymos’s “other face,” advancing precision measurement and planetary defense together.
- At AHA, pelacarsen and ziltivekimab both posted strong biomarker drops without hard-endpoint wins; J&J’s oral IL-23R peptide and China’s therapeutic HPV vaccine Phase 3 offered positive counters.
- Tibetan ground-ice “warming yet thickening” and flash-Joule blade upcycling stress that adaptation and green manufacturing must track moisture and material loops, not only temperature or installed capacity.
- Oxford’s ion gauge-theory demo and a single-molecule white OLED each open a new operable interface—one in quantum many-body physics, one in lighting materials.
Daily Framing:
Today in the science cycle was a “biomarker bust meets extreme-conditions day”—CV pipelines were reminded that cutting Lp(a)/inflammation ≠ fewer events, while picokelvin gases on Tiangong, Hera’s impact-site reconnaissance, and anomalous plateau permafrost pulled precision measurement, planetary defense, and climate adaptation back to testable physical boundaries.
This digest is compiled from real-time search results and is for reference only.